Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937290 | 1.00 | PTGER4 (0.58) | PTGER4CYP1A2CYP2D6RXRARXRB | |
| SCHEMBL4610403 | 0.94 | PTGER4 (0.64) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL12289277 | 0.92 | PTGER4 (0.48) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL14318611 | 0.92 | PTGER4 (0.48) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL12289278 | 0.92 | PTGER4 (0.48) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2937605 | 0.91 | PTGER4 (0.57) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2930321 | 0.91 | PTGER4 (0.57) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL14307440 | 0.91 | PTGER4 (0.57) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3238654 | 0.88 | PTGER4 (0.58) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3231023 | 0.88 | PTGER4 (0.58) | PTGER4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046742-B1 | BENZO [F] ISOINDOLES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-20090312388-A1 | Benzo [F] Isoindoles As EP4 Receptor Agonists | GLAXO GROUP LIMITED | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312388-A1 | Benzo [F] Isoindoles As EP4 Receptor Agonists | PTGER4, GPR4, PTGER1 | PTGER4 1/4885CYP1A2 310/4885CYP2D6 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.